Licensing & FAQs

Licensing & FAQs around COVID19-related inventions and how Duke is reducing barriers to licensing new technologies in this area.

Need to speak to a licensing representative?

Get in Touch

Licensing & Agreements

Our goal is to get our technology out to where it is needed quickly, reducing as many hurdles to licensing as we possibly can.

If you would like to use one of our technologies or software platforms, please reach out to us so we can help get this facilitated.

Get in touch

Research FAQs

  1. Human Subjects/Clinical Research- On Monday, March 16, the Duke School of Medicine Clinical Research Administration initiated the Essential Clinical Research Study Policy. At that time, all in-person clinical research study activities for Tier 3, non-essential, studies were temporarily suspended until further notice. While other clinical research activities that can be done virtually or remotely are able to continue, participant in-person visits are not allowed.
  2. For studies in the Campus Institutional Review Board (IRB)

USPTO FAQs

Patents and Patent Trial and Appeal Board (PTAB) FAQs: Extension of Deadlines under the CARES Act

See FAQs


Trademarks and Trademark Trial and Appeal Board (TTAB) FAQs: Extension of Deadlines under the CARES Act

See FAQs